Table of Content

1 Key Insights

2 Executive Summary of Narcolepsy

3 SWOT Analysis for Narcolepsy

4 Narcolepsy Epidemiology Overview at a Glance
4.1 Patient Share (%) Distribution of Narcolepsy in 2017
4.2 Patient Share (%) Distribution of Narcolepsy in 2030

5 Narcolepsy Market Overview at a Glance
5.1 Market Share (%) Distribution of Narcolepsy in 2017
5.2 Market Share (%) Distribution of Narcolepsy in 2030

6 Disease Background and Overview: Narcolepsy
6.1 Introduction
6.2 Signs and Symptoms
6.3 Complications
6.4 Pathophysiology
6.5 Etiology
6.6 Risk Factors
6.7 Diagnosis

7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Population and Forecast Parameters

8 7MM Total Prevalent Patient Population of Narcolepsy
8.1 The United States
8.1.1 Diagnosed Prevalent Patient Population of Narcolepsy in the United States
8.1.2 Subtype-specific cases of Narcolepsy in the United States
8.1.3 Clinical Manifestations associated with Narcolepsy
8.1.4 Age-group wise Prevalence of Narcolepsy
8.2 Germany
8.2.1 Diagnosed Prevalent Patient Population of Narcolepsy in Germany
8.2.2 Subtype-specific cases of Narcolepsy in Germany
8.2.3 Clinical Manifestations associated with Narcolepsy
8.2.4 Age-group wise Prevalence of Narcolepsy
8.3 France
8.3.1 Diagnosed Prevalent Patient Population of Narcolepsy in France
8.3.2 Subtype-specific cases of Narcolepsy in France
8.3.3 Clinical Manifestations associated with Narcolepsy
8.3.4 Age-group wise Prevalence of Narcolepsy
8.4 Italy
8.4.1 Diagnosed Prevalent Patient Population of Narcolepsy in Italy
8.4.2 Subtype-specific cases of Narcolepsy in Italy
8.4.3 Clinical Manifestations associated with Narcolepsy
8.4.4 Age-group wise Prevalence of Narcolepsy
8.5 Spain
8.5.1 Diagnosed Prevalent Patient Population of Narcolepsy in Spain
8.5.2 Subtype-specific cases of Narcolepsy in Spain
8.5.3 Clinical Manifestations associated with Narcolepsy
8.5.4 Age-group wise Prevalence of Narcolepsy
8.6 United Kingdom
8.6.1 Diagnosed Prevalent Patient Population of Narcolepsy in the United Kingdom
8.6.2 Subtype-specific cases of Narcolepsy in the United Kingdom
8.6.3 Clinical Manifestations associated with Narcolepsy
8.6.4 Age-group wise Prevalence of Narcolepsy
8.7 Japan
8.7.1 Diagnosed Prevalent Patient Population of Narcolepsy in Japan
8.7.2 Subtype-specific cases of Narcolepsy in Japan
8.7.3 Clinical Manifestations associated with Narcolepsy
8.7.4 Age-group wise Prevalence of Narcolepsy

9 Treatment and Management
9.1 Guideline and Management
9.1.1 American Academy of Sleep Medicine Guidelines
9.1.2 European Federation of Neurological Societies (EFNS) Guidelines

10 Unmet Needs

11 Marketed Products
11.1 Provogil: Cephalon Inc.
11.1.1 Drug Description
11.1.2 Regulatory Milestones
11.1.3 Product Profile
11.2 Xyrem: Jazz Pharmaceuticals
11.2.1 Product Description
11.2.2 Regulatory Milestones
11.2.3 Advantages and Disadvantages
11.2.4 Product Profile
11.3 JZP-258: Jazz Pharmaceuticals Inc.
11.3.1 Drug Description
11.3.2 Regulatory Milestones
11.3.3 Clinical Development
11.3.6 Product Profile
11.4 JZP-110: Jazz Pharmaceuticals
11.4.1 Product Description
11.4.2 Regulatory Milestones
11.4.3 Product Profile

12 Other Narcoleptics
12.1 Anafranil (clomipramine)
12.1.1 Product Description
12.1.2 Regulatory Milestones
12.1.3 Advantages and Disadvantages
12.2 Desipramine
12.2.1 Product Description
12.2.2 Regulatory Milestones
12.2.3 Advantages and Disadvantages
12.2.4 Product Profile
12.3 Prozac (Fluoxetine)
12.3.1 Product Description
12.3.2 Regulatory Milestones
12.3.3 Advantages and Disadvantages
12.3.4 Product Profile
12.4 Tofranil (Imipramine)
12.4.1 Product Description
12.4.2 Advantages and Disadvantages
12.4.3 Product Profile
12.5 Vivactil (Protriptyline)
12.5.1 Product Description
12.5.2 Regulatory Milestones
12.5.3 Advantages and Disadvantages
12.5.4 Product Profile
12.6 Zoloft (Sertraline)
12.6.1 Product Description
12.6.2 Regulatory Milestones
12.6.3 Advantages and Disadvantages
12.6.4 Product Profile
12.7 Effexor (Venlafaxine)
12.7.1 Product Description
12.7.2 Regulatory Milestones
12.7.3 Advantages and Disadvantages
12.7.4 Product Profile
12.8 Desoxyn (Methamphetamine)
12.8.1 Product Description
12.8.2 Regulatory Milestones
12.8.3 Advantages and Disadvantages
12.8.4 Product Profile
12.9 NUVIGIL
12.9.1 Product Description
12.9.2 Regulatory Milestones
12.9.3 Advantages and Disadvantages
12.9.4 Product Profile
12.1 Wakix (Pitolisant)
12.10.1 Product Description
12.10.2 Regulatory Milestones
12.10.3 Advantages and Disadvantages
12.10.4 Product Profile
12.11 Ritalin
12.11.1 Product Description
12.11.2 Regulatory Milestones
12.11.3 Advantages and Disadvantages
12.11.4 Product Profile
12.12 Dexedrine
12.12.1 Product Description
12.12.2 Regulatory Milestones
12.12.3 Advantages and Disadvantages
12.12.4 Product Profile
12.13 Adderall
12.13.1 Product Description
12.13.2 Regulatory Milestones
12.13.3 Advantages and Disadvantages
12.13.4 Product Profile
12.14 Atomoxetine
12.14.1 Product Description
12.14.2 Regulatory Milestones
12.14.3 Advantages and Disadvantages
12.14.4 Product Profile

13 Emerging Drugs
13.1 Sodium oxybate ER: Avadel Pharmaceuticals
13.1.1 Product Description
13.1.2 Regulatory Milestones
13.1.3 Clinical Development
13.1.4 Safety and efficacy
13.1.5 Product Profile
13.2 AXS-12 (Reboxetine): Axsome Therapeutics
13.2.1 Product Description
13.2.2 Regulatory Milestones
13.2.3 Clinical Development
13.2.4 Safety and efficacy
13.2.5 Product Profile

14 Other Promising Candidates
14.1 SUVN-G3031: Suven Life Sciences Limited
14.1.1 Product description
14.1.2 Clinical Development
14.1.3 Safety and Efficacy
14.2 TAK-994: Takeda
14.2.1 Product description
14.2.2 Clinical Development
14.3 TAK-925: Takeda
14.3.1 Product Description
14.3.2 Clinical Development
14.3.3 Safety and Efficacy
14.4 ADAIR: Vallon Pharmaceuticals
14.4.1 Product Description
14.4.2 Clinical Development
14.4.3 Safety and Efficacy
14.5 Mazindol CR: NLS Pharma
14.5.1 Product Description
14.5.2 Product Development Activities
14.5.3 Product Profile
15 No Development Reported
15.1 BTD – 001: Balance Therapeutics
15.1.1 Product Description
15.1.2 Clinical Development
15.1.3 Clinical Trial Information
15.1.4 Product Profile
15.2 TS-091: Taisho Pharmaceutical Co
15.2.1 Product Description
15.2.2 Clinical Development
15.2.3 Product Profile
15.3 THN102 (Modafinil + Flecainide): Theranexus
15.3.1 Regulatory Milestones
15.3.2 Clinical Development
15.3.3 Clinical Trial Information
15.3.4 Product Profile
16 Narcolepsy: 7 Major Market Analysis
16.1 Key Findings
16.2 Market Size of Narcolepsy in 7MM
17 7MM: Narcolepsy Market Outlook
18 Country-wise Market Analysis
18.1 The United States
18.1.1 Total Market size of Narcolepsy in the U.S.
18.1.2 Therapy-based market size of Narcolepsy in the U.S.
18.2 EU-5 Countries
18.2.1 Germany
18.2.2 France
18.2.3 Italy
18.2.4 Spain
18.2.5 United Kingdom
18.3 Japan
18.3.1 Total Market size of Narcolepsy in Japan
18.3.2 Therapy-based market size of Narcolepsy in Japan
19 Market Drivers
20 Market Barriers
21 Appendix
21.1 Report Methodology
22 DelveInsight Capabilities
23 Disclaimer
24 About DelveInsight



List of Figures


Figure 1: SWOT Analysis
Figure 2: Complications of Narcolepsy
Figure 3: Pathophysiology of Narcolepsy
Figure 4: Prevalent Cases of Narcolepsy in the 7MM (2017–2030)
Figure 5: Diagnosed Prevalent Cases of Narcolepsy in the United States (2017–2030)
Figure 6: Subtype-specific cases of Narcolepsy in the United States (2017–2030)
Figure 7: Clinical Manifestations associated with Narcolepsy in the United States (2017–2030)
Figure 8: Age-group wise Prevalence of Narcolepsy (2017–2030)
Figure 9: Diagnosed Prevalent Cases of Narcolepsy in Germany (2017–2030)
Figure 10: Subtype-specific cases of Narcolepsy in Germany (2017–2030)
Figure 11: Clinical Manifestations associated with Narcolepsy in Germany (2017–2030)
Figure 12: Age-group wise Prevalence of Narcolepsy (2017–2030)
Figure 13: Diagnosed Prevalent Cases of Narcolepsy in France (2017–2030)
Figure 14: Subtype-specific cases of Narcolepsy in France (2017–2030)
Figure 15: Clinical Manifestations associated with Narcolepsy in France (2017–2030)
Figure 16: Age-group wise Prevalence of Narcolepsy (2017–2030)
Figure 17: Diagnosed Prevalent Cases of Narcolepsy in Italy (2017–2030)
Figure 18: Subtype-specific cases of Narcolepsy in Italy (2017–2030)
Figure 19: Clinical Manifestations associated with Narcolepsy in Italy (2017–2030)
Figure 20: Age-group wise Prevalence of Narcolepsy (2017–2030)
Figure 21: Diagnosed Prevalent Cases of Narcolepsy in Spain (2017–2030)
Figure 22: Subtype-specific cases of Narcolepsy in Spain (2017–2030)
Figure 23: Clinical Manifestations associated with Narcolepsy in Spain (2017–2030)
Figure 24: Age-group wise Prevalence of Narcolepsy (2017–2030)
Figure 25: Diagnosed Prevalent Cases of Narcolepsy in the United Kingdom (2017–2030)
Figure 26: Subtype-specific cases of Narcolepsy in the United Kingdom (2017–2030)
Figure 27: Clinical Manifestations associated with Narcolepsy in the United Kingdom (2017–2030)
Figure 28: Age-group wise Prevalence of Narcolepsy (2017–2030)
Figure 29: Diagnosed Prevalent Cases of Narcolepsy in Japan (2017–2030)
Figure 30: Subtype-specific cases of Narcolepsy in Japan (2017–2030)
Figure 31: Clinical Manifestations associated with Narcolepsy in Japan (2017–2030)
Figure 32: Age-group wise Prevalence of Narcolepsy (2017–2030)
Figure 33: Decision tree for starting and then adapting the therapy for excessive daytime sleepiness and cataplexy
Table 34: Therapies for the treatment of Excessive daytime sleepiness and irresistible episodes of sleep with Narcolepsy
Figure 35: Non pharmacological treatment practices for Narcolepsy
Figure 36: Unmet Needs for Narcolepsy
Figure 37: 7 Major Market Size of Narcolepsy in USD million (2017–2030)
Figure 38: Market Size of Narcolepsy in the US, in USD million (2017–2030)
Figure 39: Therapy-based Market Size of Narcolepsy in the US, in USD million (2017–2030)
Figure 40: Market Size of Narcolepsy in Germany, USD millions (2017–2030)
Figure 41: Therapy-based Market Size of Narcolepsy in Germany, in USD million (2017–2030)
Figure 42: Market Size of Narcolepsy in France, in USD million (2017–2030)
Figure 43: Therapy-based Market Size of Narcolepsy in France, in USD million (2017–2030)
Figure 44: Market Size of Narcolepsy in Italy, in USD million (2017–2030)
Figure 45: Therapy-based Market Size of Narcolepsy in Italy, in USD million (2017–2030)
Figure 46: Market Size of Narcolepsy in Spain, in USD million (2017–2030)
Figure 47: Therapy-based Market Size of Narcolepsy in Spain, in USD million (2017–2030)
Figure 48: Market Size of Narcolepsy in the UK, USD millions (2017–2030)
Figure 49: Therapy-based Market Size of Narcolepsy in the UK, in USD million (2017–2030)
Figure 50: Market Size of Narcolepsy in Japan, in USD million (2017–2030)
Figure 51: Therapy-based Market Size of Narcolepsy in Japan, in USD million (2017–2030)
Figure 52: Market Drivers
Figure 53:Market Barriers

 

List of Tables


Table 1: Summary of Narcolepsy, Epidemiology, and Key Events (2017–2030)
Table 2:Total Prevalent Patient Population of Narcolepsy in the 7MM (2017–2030)
Table 3: Prevalent Cases of Narcolepsy in the United States (2017–2030)
Table 4: Subtype-specific cases of Narcolepsy in the United States (2017–2030)
Table 5: Clinical Manifestations associated with Narcolepsy in the United States (2017–2030)
Table 6: Age-group wise Prevalence of Narcolepsy (2017–2030)
Table 7: Prevalent Cases of Narcolepsy in Germany (2017–2030)
Table 8: Subtype-specific cases of Narcolepsy in Germany (2017–2030)
Table 9:Clinical Manifestations associated with Narcolepsy in Germany (2017–2030)
Table 10: Age-group wise Prevalence of Narcolepsy (2017–2030)
Table 11: Prevalent Cases of Narcolepsy in France (2017–2030)
Table 12: Subtype-specific cases of Narcolepsy in France (2017–2030)
Table 13: Clinical Manifestations associated with Narcolepsy in France (2017–2030)
Table 14: Age-group wise Prevalence of Narcolepsy (2017–2030)
Table 15: Prevalent Cases of Narcolepsy in Italy (2017–2030)
Table 16:Subtype-specific cases of Narcolepsy in Italy (2017–2030)
Table 17: Clinical Manifestations associated with Narcolepsy in Italy (2017–2030)
Table 18: Age-group wise Prevalence of Narcolepsy (2017–2030)
Table 19: Prevalent Cases of Narcolepsy in Spain (2017–2030)
Table 20: Subtype-specific cases of Narcolepsy in Spain (2017–2030)
Table 21: Clinical Manifestations associated with Narcolepsy in Spain (2017–2030)
Table 22: Age-group wise Prevalence of Narcolepsy (2017–2030)
Table 23: Prevalent Cases of Narcolepsy in the United Kingdom (2017–2030)
Table 24:Subtype-specific cases of Narcolepsy in the United Kingdom (2017–2030)
Table 25: Clinical Manifestations associated with Narcolepsy in the United Kingdom (2017–2030)
Table 26: Age-group wise Prevalence of Narcolepsy (2017–2030)
Table 27: Prevalent Cases of Narcolepsy in Japan (2017–2030)
Table 28: Subtype-specific cases of Narcolepsy in Japan (2017–2030)
Table 29: Clinical Manifestations associated with Narcolepsy in Japan (2017–2030)
Table 30: Age-group wise Prevalence of Narcolepsy in Japan (2017–2030)
Table 31: Sodium oxybate, Clinical Trial Description
Table 32: AXS-12, Clinical Trial Description
Table 33: BTD-001 Clinical Trial Description
Table 34: TS-091 Clinical Trial Description
Table 35: THN102 Clinical Trial Description
Table 36: 7 Major Market Size of Narcolepsy in USD million (2017–2030)
Table 37: Market Size of Narcolepsy in the United States, USD million (2017–2030)
Table 38: Therapy-based Market Size of Narcolepsy in the US, in USD million (2017–2030))
Table 39: Market Size of Narcolepsy in Germany, in USD million (2017–2030)
Table 40: Therapy-based Market Size of Narcolepsy in Germany, in USD million (2017–2030))
Table 41: Market Size of Narcolepsy in France, in USD million (2017–2030)
Table 42: Therapy-based Market Size of Narcolepsy in France, in USD million (2017–2030)
Table 43: Market Size of Narcolepsy in Italy, in USD million (2017–2030)
Table 44: Therapy-based Market Size of Narcolepsy in Italy, in USD million (2017–2030))
Table 45: Market Size of Narcolepsy in Spain, in USD million (2017–2030)
Table 46: Therapy-based Market Size of Narcolepsy in Spain, in USD million (2017–2030))
Table 47: Market Size of Narcolepsy in the UK, in USD million (2017–2030)
Table 48: Therapy-based Market Size of Narcolepsy in the UK, in USD million (2017–2030))
Table 49: Market Size of Narcolepsy in Japan, in USD million (2017–2030)
Table 50: Therapy-based Market Size of Narcolepsy in in Japan, in USD million (2017–2030)